Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

To be able to join this study, your doctor will need to check a few things. You must have bowel cancer that has spread to other parts of your body, and this must be your first time receiving treatment for it. You should also be generally well enough to take part, meaning you can carry out most of your daily activities without much trouble, and doctors expect you to live for at least another six months. Your cancer also needs to have at least one area that can be measured on scans.

There are also some reasons why you might not be able to join. For example, if your bowel cancer has certain genetic markers (like MSI-High, dMMR, or BRAF V600E mutations), you won't be eligible. You also can't have serious bowel blockages or conditions like inflammatory bowel disease (Crohn's or ulcerative colitis). If you've already had certain types of cancer treatment, like immunotherapy or anti-angiogenic therapy, or if your cancer could be completely removed by surgery, you won't be able to join this particular study.

If you join this study, you'll be randomly put into one of two groups, like flipping a coin. Neither you nor your doctor will know which treatment group you are in. Both groups will receive regular treatments given through a drip into your vein.

For the first part of the study, you'll receive your assigned drug (either ivonescimab or bevacizumab) along with a chemotherapy called mFOLFOX6. This will be given every two weeks for up to 8 cycles. After this, you'll continue with a maintenance treatment of your assigned drug plus two chemotherapy drugs (5-Fluorouracil and Leucovorin) every two weeks. This maintenance treatment could last for up to two years. Throughout the study, you'll have regular hospital visits for your treatments, check-ups, and tests to monitor your health and how the treatment is working.